Sax Wealth Advisors LLC Invests $561,000 in Illumina, Inc. (NASDAQ:ILMN)

Sax Wealth Advisors LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 4,198 shares of the life sciences company's stock, valued at approximately $561,000.

A number of other hedge funds have also bought and sold shares of the business. Millennium Management LLC boosted its holdings in Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company's stock worth $155,067,000 after purchasing an additional 1,118,747 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Illumina during the 2nd quarter valued at $77,628,000. Massachusetts Financial Services Co. MA lifted its holdings in shares of Illumina by 148.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company's stock valued at $137,735,000 after buying an additional 631,294 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock worth $282,735,000 after buying an additional 625,245 shares during the last quarter. Finally, Iron Triangle Partners LP bought a new stake in shares of Illumina in the third quarter worth $57,380,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Price Performance

ILMN traded down $0.70 during trading on Friday, reaching $136.67. 1,247,185 shares of the company traded hands, compared to its average volume of 1,836,016. The company has a market cap of $21.68 billion, a P/E ratio of -13.72 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66. The firm has a fifty day simple moving average of $139.60 and a 200 day simple moving average of $133.57.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina's quarterly revenue was down 3.5% on a year-over-year basis. During the same period last year, the company posted $0.33 earnings per share. On average, equities analysts forecast that Illumina, Inc. will post 4.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ILMN. UBS Group boosted their price target on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Citigroup cut shares of Illumina from a "buy" rating to a "neutral" rating and reduced their target price for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. Royal Bank of Canada increased their price target on shares of Illumina from $252.00 to $254.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. Finally, Hsbc Global Res raised shares of Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $165.63.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.